ストックスクリーナーアプリを入手
5.58
0.18%
0.010
アフターアワーズ：
5.58
前日終値:
$5.57
開ける：
$5.5
24時間の取引高:
150.97K
Relative Volume:
0.77
時価総額：
$90.28M
収益：
-
当期純損益:
$-64.47M
株価収益率:
-0.9022
EPS:
-6.1852
ネットキャッシュフロー:
$-52.33M
1週間 パフォーマンス:
-7.15%
1か月 パフォーマンス:
+15.77%
6か月 パフォーマンス:
-72.91%
1年 パフォーマンス:
-77.07%
1日の値動き範囲:
$5.43
$5.65
1週間の範囲:
$5.40
$6.125
52週間の値動き範囲:
$3.1301
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
名前
Jasper Therapeutics Inc
セクター
電話
(650) 549-1400
住所
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
5.58 | 90.28M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-09-09 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-08 | 開始されました | BTIG Research | Buy |
| 2024-06-27 | 開始されました | Stifel | Buy |
| 2024-05-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-03 | 開始されました | Evercore ISI | Outperform |
| 2024-03-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-18 | 開始されました | TD Cowen | Outperform |
| 2023-08-11 | 開始されました | CapitalOne | Overweight |
| 2022-02-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Credit Suisse | Outperform |
| 2021-10-21 | 開始されました | William Blair | Outperform |
| 2021-10-20 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-13 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Jasper Therapeutics Inc (JSPR) 最新ニュース
JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | - GuruFocus
Jasper Therapeutics Reports Positive Data from 180mg Cohort - GlobeNewswire
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire Inc.
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinized - Investing.com Canada
Cantor Fitzgerald Weighs in on JSPR FY2026 Earnings - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
Wellington Management Group LLP Boosts Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Trend Tracker for (JSPR) - news.stocktradersdaily.com
Is Monster Beverage Stock Outperforming the S&P 500? - The Globe and Mail
Jane Street Group LLC Sells 2,502 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Warren Buffett Is Ready to Invest $100 Billion in a Stock That Meets These 3 Criteria - The Globe and Mail
Jasper Therapeutics Announces Acceptance of Four Abstracts for Presentation at EAACI Congress 2025 - Nasdaq
Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire
Breakthrough Clinical Data: Jasper's Briquilimab Shows Promise in Treating Resistant Urticaria Cases - Stock Titan
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely - Yahoo Finance
Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market - TipRanks
Bank of America Corp DE Cuts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Northern Trust Corp Trims Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Market Analysis: May 26th, 2025 - The Globe and Mail
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment - Investing.com Canada
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment By Investing.com - Investing.com South Africa
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential - Insider Monkey
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stake Lifted by Deutsche Bank AG - Defense World
Spotify Stock's Rally Still Has Legs To Run Higher - The Globe and Mail
Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR - Defense World
Oppenheimer Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $65.00 - Defense World
Jasper Therapeutics (JSPR) Price Target Lowered by Oppenheimer | JSPR Stock News - GuruFocus
(JSPR) Trading Report - news.stocktradersdaily.com
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
William Blair Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q2 EPS Forecast for Jasper Therapeutics Increased by Analyst - Defense World
Oppenheimer Cuts Price Target on Jasper Therapeutics to $65 From $80, Keeps Outperform Rating - marketscreener.com
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) - GuruFocus
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News - GuruFocus
Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development - Nasdaq
Jasper Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics Showcases Novel Antibody Therapy at Major Healthcare Conferences This Summer - Stock Titan
UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News - GuruFocus
JSPR Price Target Adjusted by UBS Amidst Upcoming Clinical Updates | JSPR Stock News - GuruFocus
Jasper (JSPR) Advances Briquilimab with Promising Trial Results - GuruFocus
UBS Adjusts Price Target on Jasper Therapeutics to $33 From $38, Maintains Buy Rating - marketscreener.com
Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics (JSPR) to Release Quarterly Earnings on Tuesday - Defense World
Wells Fargo & Company MN Purchases 3,828 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $62.50 - Defense World
JPMorgan Chase & Co. Sells 11,226 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
(JSPR) Trading Advice - news.stocktradersdaily.com
JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Jasper Therapeutics Inc (JSPR) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):